$VTRS News

Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam

Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

1 Stock Under $50 to Target This Week and 2 We Avoid

5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For Review

Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)?

3 Unprofitable Stocks That Fall Short

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance

TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle

JP Morgan Maintains Neutral on Viatris, Raises Price Target to $18

Truist Securities Maintains Buy on Viatris, Raises Price Target to $20

Viatris Inc. Q1 2026 Earnings Call Summary

Assessing Viatris (VTRS) Valuation After Its Recent Share Price Rebound

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris (VTRS) Q1 2026 Earnings Transcript